Navigation Links
'Smart drug' targets deadly brain cancer

A study led by Mayo Clinic researchers and conducted by the North Central Cancer Treatment Group (NCCTG) reports that a new "smart" drug treatment for an incurable form of recurrent brain cancer slowed tumor growth in more than one-third of the 65 adult patients who tried it. The same research team also developed a screening technique to help predict which patients will respond best to this treatment.

Mayo researchers will present these findings at the 2005 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fla. The NCCTG study addressed the most common kind of tumor arising from brain tissue of adults, glioblastoma mutiforme. Current treatment outcomes for this type of cancer are extremely poor: median patient survival is 12 to 16 months, and recurrent disease has a dismal prognosis. The World Health Organization categorizes fast-growing glioblastoma multiforme as a grade IV cancer.

Significance of the Mayo Clinic/NCCTG Research

This discouraging prognosis may change as a result of the rational foundation for new therapies the NCCTG research provides. Study data showed that in 36 percent of patients suffering from recurrent glioblastoma multiforme, the new "smart" drug behaved as hypothesized: It found its target -- tumor cells -- and actively worked against them to slow tumor growth.

According to the study's lead investigator, Mayo Clinic medical oncologist Evanthia Galanis, M.D., "Treatment was well tolerated, and imaging responses were observed in a significant portion (36 percent) of patients with recurrent glioblastoma multiforme participating in this study -- which is a high response rate for this very resistant disease. These early results suggest that we are on to a promising new treatment strategy that could potentially help us improve treatment for patients with recurrent glioblastoma."

Achieving the 36 percent regression rate was an encouraging result -- but researchers didn't stop there. They t
'"/>

Source:Mayor Clinic


Page: 1 2 3

Related biology news :

1. Smart nanoprobes light up disease
2. Smart genetic therapy helps the body to heal itself
3. Anti-inflammatory drugs potentially deadly side effect found to be rare
4. Chemical maps hint at drugs effects on schizophrenia
5. A bacterial genome reveals new targets to combat infectious disease
6. Study reveals candidate targets for anti-retroviral therapeutics
7. NHGRI targets 12 more organisms for genome sequencing
8. Moffitt-USF head toward first human trials of anti-cancer drug that targets protein AKT
9. Novel targets found for the development of drugs to complement, or replace, statins
10. Vaccine targets tumors where they live
11. Study findings offer potential new targets for antibiotics
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Smart drug targets deadly brain cancer

(Date:9/30/2014)... know what goes wrong with your muscles because of age, ... "normal" actually is. That,s where a new research report published ... Journal comes in. In the report, a team ... that can help scientists "see" which genes are active in ... never-before-detected gene activity and that men have approximately 400 more ...
(Date:9/30/2014)... HEIGHTS, Ill. (September 30, 2014) People who suffer ... can do to control their asthma besides properly taking ... a new article in the Annals of Allergy, ... American College of Allergy, Asthma and Immunology (ACAAI), asthma ... examining their lifestyle. The woman described in the Annals ...
(Date:9/29/2014)... Monday, September 29: Between 1970 and 2010 ... around the globe dropped 52 percent, says the ... Wildlife Fund (WWF). This biodiversity loss occurs disproportionately ... use of high-income countries. , In addition to ... data point to other warning signs about the ...
Breaking Biology News(10 mins):Scientists identify which genes are active in muscles of men and women 2Asthma symptoms kicking up? Check your exposure to air pollution 2Half of global wildlife lost, says new WWF report 2
... The Field Museum announced today that it has received 409,416 ... of Monaco Foundation for a three-year project: Establishing new conservation ... biological inventories by The Field Museum,s Environment, Culture, and Conservation ... landscapes in Ecuador, Peru, and Bolivia. Eight of these areas ...
... CryoLife, Inc. (NYSE: CRY) Elite cardiovascular surgeons from around ... the two-day Ross Summit to review and discuss current peer-reviewed ... and to practice the technical nuances required to perform this ... type of specialized aortic valve surgery in which the patient,s ...
... Rush University Medical Center is participating in a ... to determine whether a vitamin-like substance, in high doses, ... disorder that affects about one million people in the ... we have for Parkinson,s can only mask the symptoms ...
Cached Biology News:Prince Albert II of Monaco Foundation helps fund Field Museum conservation efforts in Peru 2Growing outcomes evidence spurs renewed interest in unique heart valve procedure 2Can an over-the-counter vitamin-like substance slow the progression of Parkinson's disease? 2
(Date:10/1/2014)... Weighing applications in pharmaceutical manufacturing ... product. However, while the pharmaceutical industry is one ... Good Manufacturing Practices (GMP) usually provide only broad ... to interpret these guidelines and assess process risks ... TOLEDO experts have created a new white paper, ...
(Date:10/1/2014)... The participants committed to not only creating unique business ... adjusting, tweaking and testing virtual models and 3D test ... , “I enjoyed being involved as a judge,” stated ... showed a commendable range exploring the technical capabilities of ... and the creativity of the contestants.” , Array Architects ...
(Date:10/1/2014)... (PRWEB) September 30, 2014 Award ... SoundConnect announces four new-hosted collaboration bundles that ... deliver high quality conferencing experiences for low, flat ... to choose from, businesses have optimized solutions to ... solutions include audio only minutes (1K, 5K, ...
(Date:10/1/2014)... 30, 2014 This report analyzes ... US$ Million by the following Product Segments: ... Specific end-use segments also analyzed are Pharmaceuticals ... The report provides separate comprehensive analytics for ... East, and Latin America. Annual estimates and ...
Breaking Biology Technology:Comply with Weighing-Related Regulations in Pharma Manufacturing 2Array Architects Challenges Staff to Create with 3D Printer 2SoundConnect Launches New Audio, Web and Video Bundles 2Global Specialty Enzymes Industry 2Global Specialty Enzymes Industry 3Global Specialty Enzymes Industry 4Global Specialty Enzymes Industry 5Global Specialty Enzymes Industry 6Global Specialty Enzymes Industry 7Global Specialty Enzymes Industry 8Global Specialty Enzymes Industry 9Global Specialty Enzymes Industry 10Global Specialty Enzymes Industry 11Global Specialty Enzymes Industry 12Global Specialty Enzymes Industry 13Global Specialty Enzymes Industry 14Global Specialty Enzymes Industry 15Global Specialty Enzymes Industry 16Global Specialty Enzymes Industry 17Global Specialty Enzymes Industry 18Global Specialty Enzymes Industry 19Global Specialty Enzymes Industry 20Global Specialty Enzymes Industry 21Global Specialty Enzymes Industry 22Global Specialty Enzymes Industry 23Global Specialty Enzymes Industry 24Global Specialty Enzymes Industry 25Global Specialty Enzymes Industry 26
... /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ... corporate partner, Boston Scientific Corporation (NYSE: ... Food and Drug Administration (FDA) to market its ... highly deliverable, next-generation drug-eluting stent (DES) specifically designed ...
... Senomyx, Inc. (Nasdaq: SNMX ), a leading ... develop novel flavor ingredients for the food, beverage, and ... L. Linemeyer, Ph.D., to the position of Vice President, ... in directing biology research programs and collaborative research projects ...
... Accumetrics, Inc. announces today it has signed new exclusive ... countries. Distribution of Accumetrics, VerifyNow products will be ... Austria and Switzerland; and Kordia in the Netherlands, Belgium ... life-saving antiplatelet therapies, such as aspirin, Plavix(R) and ...
Cached Biology Technology:Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system 2Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system 3Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system 4Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system 5SENOMYX ANNOUNCES APPOINTMENT OF DAVID L. LINEMEYER, PH.D., AS VICE PRESIDENT, BIOLOGY 2SENOMYX ANNOUNCES APPOINTMENT OF DAVID L. LINEMEYER, PH.D., AS VICE PRESIDENT, BIOLOGY 3Accumetrics, Inc. Announces European Distribution Channels for France, Austria, Switzerland, Netherlands, Belgium and Luxembourg 2Accumetrics, Inc. Announces European Distribution Channels for France, Austria, Switzerland, Netherlands, Belgium and Luxembourg 3
Request Info...
Purified anti-eIF-4E...
Peptide-affinity Purified Polyclonal Antibody to SMAD7 Peptide with sequence SSCPCWLEVIFNSR, from C Terminus of the protein sequence according to NP_005895....
Purified anti-PXR...
Biology Products: